These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 31643047)

  • 1. Pushing the Envelope: Advancement of ADCs Outside of Oncology.
    McPherson MJ; Hobson AD
    Methods Mol Biol; 2020; 2078():23-36. PubMed ID: 31643047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads.
    Xi M; Zhu J; Zhang F; Shen H; Chen J; Xiao Z; Huangfu Y; Wu C; Sun H; Xia G
    Eur J Med Chem; 2024 Oct; 276():116709. PubMed ID: 39068862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody drug conjugates beyond cytotoxic payloads.
    Hobson AD
    Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Overview of the Current ADC Discovery Landscape.
    Tumey LN
    Methods Mol Biol; 2020; 2078():1-22. PubMed ID: 31643046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Drug Conjugates-A Tutorial Review.
    Baah S; Laws M; Rahman KM
    Molecules; 2021 May; 26(10):. PubMed ID: 34063364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conjugations to Endogenous Cysteine Residues.
    Nadkarni DV
    Methods Mol Biol; 2020; 2078():37-49. PubMed ID: 31643048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?
    Zhang B; Wang M; Sun L; Liu J; Yin L; Xia M; Zhang L; Liu X; Cheng Y
    J Med Chem; 2024 Jul; 67(14):11469-11487. PubMed ID: 38980167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics.
    Gerber HP; Koehn FE; Abraham RT
    Nat Prod Rep; 2013 May; 30(5):625-39. PubMed ID: 23525375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement.
    Jiang M; Li Q; Xu B
    Drug Resist Updat; 2024 Jul; 75():101086. PubMed ID: 38677200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-drug conjugates: Principles and opportunities.
    Phuna ZX; Kumar PA; Haroun E; Dutta D; Lim SH
    Life Sci; 2024 Jun; 347():122676. PubMed ID: 38688384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
    Chen H; Lin Z; Arnst KE; Miller DD; Li W
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive review on the elaboration of payloads derived from natural products for antibody-drug conjugates.
    Lu N; Wu J; Tian M; Zhang S; Li Z; Shi L
    Eur J Med Chem; 2024 Mar; 268():116233. PubMed ID: 38408390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Recent Developments of ADCs with the Tubulysins as the Payloads.
    Xiangrong X; Yao L; Yao A
    Mini Rev Med Chem; 2023; 23(18):1797-1805. PubMed ID: 36825713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncialamycin as a novel payload for antibody drug conjugate (ADC) based targeted cancer therapy.
    Chowdari NS; Pan C; Rao C; Langley DR; Sivaprakasam P; Sufi B; Derwin D; Wang Y; Kwok E; Passmore D; Rangan VS; Deshpande S; Cardarelli P; Vite G; Gangwar S
    Bioorg Med Chem Lett; 2019 Feb; 29(3):466-470. PubMed ID: 30579797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads.
    Aguiar S; Dias J; Manuel AM; Russo R; Gois PMP; da Silva FA; Goncalves J
    Adv Protein Chem Struct Biol; 2018; 112():143-182. PubMed ID: 29680236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology.
    Liu SN; Li C
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):743-765. PubMed ID: 33792763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-drug conjugates come of age in oncology.
    Dumontet C; Reichert JM; Senter PD; Lambert JM; Beck A
    Nat Rev Drug Discov; 2023 Aug; 22(8):641-661. PubMed ID: 37308581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular vesicles as modifiers of antibody-drug conjugate efficacy.
    Barok M; Puhka M; Yazdi N; Joensuu H
    J Extracell Vesicles; 2021 Feb; 10(4):e12070. PubMed ID: 33613875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.